

To: 5.1.2e [5.1.2e @modernatx.com]; 5.1.2e @rivm.nl; 5.1.2e @rivm.nl; 5.1.2e [5.1.2e] [5.1.2e @minvws.nl]
Cc: 5.1.2e 5.1.2e 5.1.2e @modernatx.com; 5.1.2e 5.1.2e @eup.at; 5.1.2e 5.1.2e @modernatx.com]
From: 5.1.2e
Sent: Wed 9/1/2021 9:33:43 AM
Subject: RE: Moderna - meeting request
Received: Wed 9/1/2021 9:33:44 AM

Dear 5.1.2e

Thank you for this update.

We are happy to meet with you to discuss developments.

This Friday we have scheduled a meeting with Moderna on donations.

But I presume we than deal with other colleagues of yours?

If Friday is another type of meeting, we will come up with dates for a separate meeting.

Best regards,
 5.1.2e

Van: 5.1.2e <5.1.2e @modernatx.com> **Namens** 5.1.2e
Verzonden: maandag 23 augustus 2021 17:55
Aan: 5.1.2e @rivm.nl; 5.1.2e @rivm.nl; 5.1.2e [5.1.2e] <5.1.2e @minvws.nl>; 5.1.2e [5.1.2e] <5.1.2e @minvws.nl>; 5.1.2e [5.1.2e] <5.1.2e @minvws.nl>
CC: 5.1.2e <5.1.2e @modernatx.com>; 5.1.2e <5.1.2e @eup.at>; 5.1.2e <5.1.2e @modernatx.com>; 5.1.2e @rivm.nl
Onderwerp: Moderna - meeting request

Dear all,

I hope this finds you well.

Since we last met on 7 June, Moderna has continued to work towards finding solutions against the current COVID-19 pandemic. In particular, we have been focusing on developing a booster strategy that can tackle the variants as well as protect immunocompromised populations. If of interest, we would be delighted to meet with you and your team to discuss these developments in more detail.

Recent study results published in the Journal *Science* show that Spikevax maintains antibodies against variants of concern and interest to 6 months. Please find more details on the [study results](#) below:

- Variants studied included Alpha, Beta, Gamma, Delta, Epsilon and Iota
- Majority of participants who received primary series maintain detectable binding and functional antibodies against variants for 6 months
- These results support the final analysis of our Phase 3 trial for Spikevax, in which our COVID-19 vaccine showed 93% efficacy. Additionally, that efficacy was also shown to be durable, six months after the second dose.
- This data complements other recent observations based on real world evidence demonstrating robust longevity of clinical efficacy of the Moderna COVID-19 vaccine, effectiveness in the face of rising levels of the Delta variant of concern and in those harder to treat populations such as those people in long term care facilities, or those patients living with cancer. You can find the relevant articles linked [here](#) and [here](#).

In addition to examining Spikevax's ability to combat variants, Moderna has also worked tirelessly to offer new solutions designed specifically against the emerging variants. In our Phase 2 studies we are currently examining two different booster vaccines:

- A variant specific shot targeted at the Beta variant

- A multivalent shot containing both our authorized Spikevax vaccine and our vaccine candidate targeted at the Beta variant.

With these developments in mind, we would welcome the opportunity to speak with you and answer any questions you may have.

Please note that we have also reached out to Health Minister De Jonge for a meeting request.

Thank you in advance for your time and consideration.

Kind Regards,

5.1.2e

5.1.2e

5.1.2e

mobile:

5.1.2e

email:

5.1.2e

@modernatx.com

modernatx.com

moderna



 Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.